Karolinska Development (Sweden) Buy or Sell Recommendation

Macroaxis provides Karolinska Development AB buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Karolinska Development positions. The advice algorithm takes into account all of Karolinska Development AB available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Karolinska Development buy-and-hold prospective. Please see also Karolinska Development Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Investment Horizon


Risk Tolerance

Execute Advice
Karolinska Development AB -- Sweden Stock  

SEK 10  1.7  20.48%

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Karolinska Development AB is 'Strong Sell'.
For the selected time horizon Karolinska Development AB has a mean deviation of 5.95, semi deviation of 1.18, standard deviation of 8.0, variance of 64.03, downside variance of 10.08 and semi variance of 1.39
This buy, hold, or sell recommendation tool can be used to cross verify current analyst consensus on Karolinska Development AB and to analyze the entity potential to grow in the current economic cycle. To make sure Karolinska Development AB is not overpriced, please verify all Karolinska Development AB fundamentals including its EBITDA, Cash and Equivalents and the relationship between Gross Profit and Net Income .

Returns Distribution Density

Mean Return3.5Value At Risk-3.7037
Potential Upside20.4819Standard Deviation8.0018
 Return Density 

Karolinska Development Greeks

Alpha over DOW
= 3.5 
βBeta against DOW=(0.11) 
Overall volatility
= 7.85 
 IrInformation ratio = 0.42 

Karolinska Development Volatility Alert

Karolinska Development AB is displaying above average volatility of 8.0 over selected time horizon. Investors should scrutinize Karolinska Development AB independently to make sure intended market timing strategies are aligned with expectations about Karolinska Development volatility.
 Better Than Average     
 Worse Than Average Compare Karolinska Development to competition
FundamentalsKarolinska DevelopmentPeer Average
Return On Equity(156.17) % (15.17) %
Return On Asset(4.21) % (15.64) %
Operating Margin(547.1) % (10.91) %
Current Valuation451.4 M152.14 B
Shares Outstanding62.61 M1.43 B
Price to Earning(3.25) times40.69 times
Price to Book7.85 times14.44 times
Price to Sales61.45 times17.81 times
Revenue5.32 M9.85 B
Gross Profit5 M21.75 B
EBITDA(29.06 M)1.41 B
Net Income(87.33 M)517.71 M
Cash and Equivalents189.13 M3.89 B
Cash per Share2.95 times5.17 times
Total Debt357.55 M7.36 B
Debt to Equity868.2 % 0.72 %
Current Ratio25.5 times3.3 times
Book Value Per Share0.65 times13.64 times
Cash Flow from Operations3.41 M1.25 B
Earnings Per Share(1.57) times2.3 times
Number of Employees1310.67 K
Market Capitalization327 M29.78 B
Total Asset449 M126.86 B
Retained Earnings(1.85 B)38.24 B
Working Capital250 M3.58 B
Current Asset259 M36.8 B
Current Liabilities9 M33.34 B
Z Score-5.6708.73
Strong Sell


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Currently Unavailable

Piotroski F Score

Currently Unavailable

Financial Leverage

Risk Adjusted Performance0.1097
Market Risk Adjusted Performance(30.84)
Mean Deviation5.95
Semi Deviation1.18
Downside Deviation3.17
Coefficient Of Variation228.85
Standard Deviation8.0
Information Ratio0.4202
Jensen Alpha3.5
Total Risk Alpha(0.85)
Sortino Ratio1.06
Treynor Ratio(30.85)
Maximum Drawdown11.03
Value At Risk(3.7)
Potential Upside20.48
Downside Variance10.08
Semi Variance1.39
Expected Short fall(8.67)

Current Valuation

Karolinska Development Current Valuation Analysis
Karolinska Development AB is considered the number one company in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Pharmaceuticals And Biosciences industry is now estimated at about 26.35 Billion. Karolinska Development claims roughly 451.4 Million in current valuation contributing just under 2% to equities listed under Pharmaceuticals And Biosciences industry.